Background
Methods
Results
Name, year | Time of samples collection | Type of study | Region | Inclusion criteria of the studies included | Exclusion criteria of the studies included |
---|---|---|---|---|---|
Bleeker 2005 | 1995–2002 | Case- control study | Netherlands | Regular male sexual partners of women with CIN and men visiting the outpatient non-STD clinic | Men with a sexually transmitted disease or with anogenital cancer |
Rosenblatt 2004 | 1999–2001 | Case- control study | Brazil | Partners of women having CIN and partners of women without CIN | None |
Rombaldi 2006 | 2003–2004 | Cross- sectional study | Brazil | Male sexual partners of women with CIN | None |
Giraldo 2008 | 2003–2005 | Cross- sectional study | Brazil | Asymptomatic men who were the sexual partners of women who had a histopathological diagnosis of any low-grade squamous intraepithelial lesions (LSIL) | Sexual partners of women with high-grade lesions |
Benevolo 2008 | 2004–2006 | Cross- sectional study | Italy | Italian clinically healthy men, monogamous sexual partners of women affected previously or presently by cervical intraepithelial neoplasia (CIN1 to CIN3) and /or with a positive result of HPV DNA. | Circumcised men and men who reported any previous episode of a sexually transmitted disease. Use of condoms the last 12 months |
Guzman-Esquivel 2009 | 2004–2005 | Case- control study | Mexico | Stable male sexual partners, of women with CIN and male sexual partners of women with normal cervical uterine cytology | Men presenting with penile or genital alterations such as genital herpes pediculosis blenorragia and psoriasis and men who were HIV-positive, receiving antiviral or immuno-modulating treatment and men who had received radiotherapy or chemotherapy. Men whose samples were insufficient or inadequate for DNA extraction or if there had been technical errors during their processing. |
Martin-Ezquerra 2012 | 2006–2007 | Cross- sectional study | Spain | Heterosexual male partners of women, who had been diagnosed with a CIN II or III during the 6 months prior to enrollment | Partners of women with pregnancy and any kind immune-suppression |
Afonso 2013 | 2000–2010 | Cross- sectional study | Brazil | Female patients presenting CIN as well as their male sexual partners (Group I) and asymptomatic couples (Group II) | None |
de Lima Rocha 2012 | N/A | Cross- sectional study | Brazil | Stable male partners (for at least 6 months) of women with cytological or histopathological diagnosis of cervical squamous intraepithelial lesions associated to HPV infection. | None |
Rob 2017 | 2013–2015 | Cross- sectional study | Czech republic | Monogamous male partners of women with histologically verified CIN (grades II-III) or genital warts | Length of the current relationship, intercourse with other sexual partners and HPV vaccination |
Vargas 2016 | 2015 (3 months) | Cross- sectional study | Colombia | Women engaged in a regular relationship and presenting CIN and their sexual partners | None |
Lopez-Diez 2017 | 2013–2015 | Cross- sectional study | Spain | Asymptomatic men, more than 18 years old, not vaccinated against HPV, whose sexual partners (regular sexual intercourse more than 1 year) had presented high grade squamous cervical lesions (CIN II or CIN III in the previous 6 months) | None |
Name, Year | Title of article | Journal | Reasons for exclusion |
---|---|---|---|
Pan LJ et al.; 2018 | HPV infection of the external genitalia in men whose female partners have cervical HPV infection | Zhonghua Nan Ke Xue. 24:516–9 | Article in Chinese |
Marcellusi A et al., 2015 | Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group | CLin Ther 37:156–167 | Unrelated to the study subject |
Drabina J et al., 2015 | Prevalence of HPV DNA among male sexual partners of women diagnosed with CIN and early invasive cervical cancer | Przegl Lek, 72: 611–5 | Article in Polish |
Lorenzon L et al., 2014 | Prevalence of HPV infection among clinically healthy Italian males and genotype concordance between stable sexual partner | J Clin Virol, 60:264–9 | Overlap with a previous study by the same group, which was included (Benevolo et al. 2008). In addition, the men were stable partners of women who had been HPV/CIN positive in the past 3 years, but whose pathological data at enrolment were not available so it was not possible to distinguish the participants with HPV + partners from participants with CiN partners. |
Carestiato FN et al., 2006 | Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay | Braz J Infect Dis. 10:331–6. | Unrelated to the study subject |
Varela JA et al.; 2006 | Research on sexually transmitted infections in asymptomatic heterosexual males whose partners have cervical intraepithelial neoplasia | Actas Dermosifiliogr 97:319–22. | No HPV detection; article in Spanish |
Bleeker MC et al., 2005 | HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions | Br J Cancer 92: 1388–92 | Overlap with a study from the same research group that was included (Bleeker 2005) |
Hogewoning CJ et al., 2003 | Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. | Int J Cancer. 107: 811–6 | Unrelated to the study subject |
Bleeker MC et al., 2003 | Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia | Int J Cancer. 107:804–10. | Overlap with a study from the same research group that was included (Bleeker 2005) |
Finan RR et al., 2002 | Identification of Chlamydia trachomatis DNA in human papillomavirus (HPV) positive women with normal and abnormal cytology. | Arch Gynecol Obstet. 266:168–71 | Unrelated to the study subject |
Bleeker MC et al., 2002 | Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia | J Am Acad Dermatol. 47:351–7 | Overlap with a study from the same research group that was included (Bleeker 2005) |
Tamim H et al., 2002 | Cervicovaginal co-infections with human papillomavirus and Chlamydia trachomatis | Diagn Microbiol Infect Dis.43: 277–81 | Unrelated to the study subject |
Bleeker MC et al., 2006 | Flat penile lesions: the infectious “invisible” link in the transmission of human papillomavirus | Int J Cancer. 119:2505–12. | Overlap with the study by Bleeker MC et al., 2002 |
Franceschi S et al., 2002 | Prevalence and determinants of human papillomavirus genital infections in men | Br J Cancer 86:705–11 | Combined data collected in five case-control studies of invasive cervical cancer (ICC) and two case-control studies of cervical carcinoma in situ (CIS) all carried out by IARC., published before 2000. |
Rob et al., 2017 | Concordance of HPV-DNA in cervical dysplasia or genital warts in women and their monogamous long-term male partners | J Med Virol 89:1662–70 | Overlap with a study from the same research group that was included (Rob et al., 2017 [20]) |
Grabowski MK et al., 2016 | Partner Human Papillomavirus Viral Load and Incident Human Papillomavirus Detection in Heterosexual Couples | J Infect Dis 231:948–56 | Unrelated to the study subject |
Widdice L et al., 2013 | Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. | J Infect Dis 207:1286–94 | Unrelated to the study subject |
Tobian A et al., 2011 | Male foreskin and oncogenic human papillomavirus infection in men and their female partners | Future Microbiol 6:739–45 | Unrelated to the study subject |
Castellsagué X et al., 2002 | Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. | N Engl J Med. 346:1105–12 | Combined data collected in five case-control studies of invasive cervical cancer (ICC) and two case-control studies of cervical carcinoma in situ (CIS) all carried out by IARC., published before 2000. |
Frega A, 2006 | Prevalence of acetowhite areas in male partners of women affected by HPV and squamous intra-epithelial lesions (SIL) and their prognostic significance. A multicenter study | Anticancer Res. 26:3171–4. | Unrelated to the study subject |
Gupta A, 2006 | Human papillomavirus DNA in urine samples of women with or without cervical cancer and their male partners compared with simultaneously collected cervical/penile smear or biopsy specimens. | J Clin Virol 37:190–4 | Unrelated to the study subject |
Morales R et al., 2012 | HPV in female partners increases risk of incident HPV infection acquisition in heterosexual men in rural central Mexico | Cancer Epidemiol Biomarkers Prev. 21: 956–65 | The study group did not include women with CIN |
Nicolau SM et al., 2005 | Human papillomavirus DNA detection in male sexual partners of women with genital human papillomavirus infection | Urology 65:251–5 | The study group did not include male partners of women with CIN |
Name, year | Diagnostic approaches | Sampling methods | Methods of hpv detection | Characterization of HPV sub-types |
---|---|---|---|---|
Bleeker 2005 | Peniscopy, HPV DNA Test | Brushes from the top of the penis(glans, corona, sulcus, frenulum, inner part of the foreskin) | HPV GP5+/6+ enzyme immunoassay PCR | HR-HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. and LR-HPV: 6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 70, 71, 72, 73, 81, 82/MM4, 83, 84, CP6108 |
Rosenblatt 2004 | Peniscopy, Biopsy, HPV DNA Test | Brushes from the penile shaft, the dorsal and ventral prebalanic area, the foreskin and the urethral meatus to navicular fossa | HPV -hybrid capture | HR- HPV: 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 and LR- HPV: 6, 11, 42, 43, 44. |
Rombaldi 2006 | Peniscopy, Biopsy, HPV DNA Test | Urotest brush from urethral canal, areas identified by peniscopic images as being clinical or subclinical signifance regarding HPV, dorsal and ventral pre-glans region, preputial mucosa, penile shaft | PCR protocol which amplified a 450-bp segment of a conserved region of the L1 viral gene delineated by the MY9 and MY11 primers. For the viral typing: RLFP | N/A |
Giraldo 2008 | Peniscopy, Biopsy, HPV DNA Test | Brushes from base, body, balanopreputial folds, preputium, distal urethra | Second-generation hybrid capture | HR- HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 |
Benevolo 2008 | HPV DNA Test | Cytobrush from dorsal and ventral area of the penile shaft, external and internal surface of the prepuce, coronal sulcus, glans and distal urethra | PCR and reverse dot blot hybridization | HR- HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82. and LR-HPV: 6, 11, 40, 43, 44 |
Guzman-Esquirel 2009 | HPV DNA Test | Cytobrush from the surface of the balano-preputial groove, the glans, and with rotating movements the navicular fossa | PCR with HPV universal primers followed by RSA1 endonuclease restriction enzyme | N/A |
Martin-Ezquerra 2012 | Peniscopy, Cytology and HPV DNA Test | Brushes from the glans, corona, sulcus at baseline and after 6 months. Anal scrapings obtained from anus at baseline. Urine samples obtained at baseline | HCII assay | N/A |
Afonso, 2013 | Peniscopy, Biopsy, HPV DNA Test | Urotest brush in areas identified by peniscopic images as being of clinical or subclinical significance | HPV detection: PCR using consensus primers MY09/11, HPV genotyping: PCR with primers for the E6 gene DNA sequence of HPV6,11,16, 18, 31,33,35,45,58 | HR-HPV:16, 18, 31, 33, 35, 45, 58 and LR- HPV:6, 11, |
de Lima Rocha 2012 | HPV DNA test | Brushes from the glans and prepuce internal surfaces, including the sulcus and the corona | PCR using GP5+/GP6+ for HPV-DNA detection, followed by PCR using primers specific for 6/11, 16, 18, 31, 33 and 45 | HR-HPV:16, 18, 31, 33, 45 and LR- HPV:6, 11, |
Rob 2017 | HPV DNA Test | FLOQ Swabs brush from the glans of penis, foreskin, urethral orifice, body of the penis and scrotum | PCR with broad spectrum primers and reverse line blot hybridization | HR- HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, Probably HR- HPV: 26, 53, 66, 67, 70, 73 and LR-HPV: 6, 11, 32, 40, 42, 43, 44, 54, 61, 62, 72, 74, 81, 90 |
Vargas 2016 | HPV DNA Test | Self -obtained penile samples, collected with a sterile nylon cytobrush from the penile groove area, the glans penis, penile body and prepuce | Linear Array HPV Genotyping Test (Roche Diagnostics, Indianapolis, Indiana, USA) | HR-HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and LR- HPV:6, 11, 26, 40 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and CP6108 |
Lopez-Diez 2017 | HPV DNA Test | Cytobrush from the dorsal and ventral area of the penile, external and internal surface of prepuce, coronal sulcus, glans and distal urethra | Linear Array HPV Genotyping Test (Linear Array, Roche Diagnostics, Mannheim, Germany) | HR- HPV: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82-including IS39 subtype |
Name, year | Number of male partners of women with CIN | Mean age | Number of women | Mean age | CIN classification | Clinical symptoms in men | Duration of relationship |
Stable relations
|
Circumcised
| Condom use | Number of sexual partners up to the date of survey |
---|---|---|---|---|---|---|---|---|---|---|---|
Bleeker 2005 | 238 | 37.6y | N/A | N/A | N/A | N/A | N/A | N/A | 5% | N/A | N/A |
Rosenblatt 2004 | 30 | N/A | 30 | N/A | CIN I: 15, CIN II: 7 and CIN III: 8 | N/A | At least 2 years | Monogamous relationship for at least 2 years | N/A | N/A | N/A |
Rombaldi 2006 | 99 | 31.7y | N/A | N/A | N/A | N/A | N/A | N/A | 8% | 40% | 50% had 1–10 partners 50% had > 10 partners |
Giraldo 2008 | 54 | 29y | N/A | N/A | LSIL | Asymptomatic | N/A | N/A | N/A | N/A | N/A |
Benevolo 2008 | 58 | 37.6y | 58 | N/A | previous CIN (not longer than 12 months): 31, CIN/ condylomatosis: 27 | Asymptomatic | At least 1 year | Monogamous relationship | Exclusion criteria | Exclusion criteria | N/A |
Guzman-Esquivel 2009 | 21 | N/A | 21 | N/A | LSIL | N/A | At least 1 year | Monogamous relationship | N/A | N/A | N/A |
Martin-Ezquerra 2012 | 91 | 34.3y | N/A | N/A | CIN II or III during the 6 months prior to enrolment | N/A | N/A | N/A | N/A | 29% | 10 partners |
Afonso 2013 | 60 | 38.6y | 60 | 34.7y | CIN I: 25, CIN II: 21 and CIN III: 14 | N/A | N/A | N/A | N/A | 21.1% | N/A |
de Lima Rocha 2012 | 43 | N/A | 23 | N/A | 20 LSIL and 3 HSIL | Asymptomatic | At least 6 months | 81% Monogamous relationship | 7% | 14% | N/A |
Rob 2017 | 41 | 32.4y | N/A | N/A | CIN grade II and III; GW | N/A | At least 6 months | Monogamous relationship | N/A | 50% | 59.2%: 1–10 partners: 40.8%: > 10 partners: |
Vargas 2016 | 25 | 36.9y | 25 | 30.6y | ASCUS: 15, LSIL: 8, HSIL:2 | N/A | At least 6 months | N/A | N/A | N/A | N/A |
Lopez-Diez 2017 | 125 | 38.2y | 125 | 35.3y | CIN II: 55 CIN III /CIS: 70 | Asymptomatic | At least 1 year | Non- obligatory monogamous relationship | N/A | N/A | 23.2% 1–5 partners: 76.8% > 5 partners: |
Name, year
| Positive peniscopy in partners of women with CIN | HPV DNA by brushing in partners with CIN % | HPV DNA test from urine | HPV DNA test from biopsy | Most other frequent detected subtype subtypes | Number of samples positive for HR vs LR-HPV |
---|---|---|---|---|---|---|
Bleeker 2005 | 139/238 (58.4%) | 101/170b (59.4%) | N/A | N/A | HPV 16 6,31,33,18 | 81/101 (80.2%) HR vs 32/101 (31.6%) LRa |
Rosenblatt 2004 | 5/30 (16.7%) | 7/30 (23%) | N/A | 3/30 (10%) | N/A | 3/7 (42.8%) HR vs 4/7 (57.2%) LR |
Rombaldi 2006 | 62/99 (62.6%) | 54/99 (54.5%) | N/A | N/A | HPV 6 11,16,40,61,84 | 2/54 (3.7%) HR vs 52/54 (96.3%) LR |
Giraldo 2008 | 13/54 (24%) | 14/54 (25.9%) | N/A | N/A | N/A | Only HR subtypes tested |
Benevolo 2008 | N/A | 25/54b (46.2%) | N/A | N/A | HPV 16 51,52,53,56,58,59 31,33,34,35,39,66, 68,73,82,6,11,40,43,44 | 22/25 (88%) HR vs 3/25 (12%) LR |
Guzman-Esquivel 2009 | N/A | 4/21 (19%) | N/A | N/A | N/A | 1/4 (25%) HR vs 3/4 (75%) LR |
Martin-Ezquerra 2012 | 11/91 (12%) | 8/62b (12.9%) | 22/78b (28%) | N/A | N/A | N/A |
Afonso 2013 | 22/60 (36.7%) | 30/60 (50%) | N/A | N/A | HPV 16 45,18 | 18/30 (60%) HR vs 15/30 (50%) LRa |
de Lima Rocha 2012 | N/A | 37/43 (86%) | N/A | N/A | HPV 16 6,11,31,18,33,45 | 29/37 (78.3%) HR vs 23/37 (62.1%) LRa |
Rob 2017 | N/A | 26/36b (72.2%) | Ν/Α | Ν/Α | HPV 16 6,11,18,30,31,33, 35,39,40,42,51,52, 53,54,56,58,59,68, 70,73,74,81,82,90 | 23/26 (88.4%) HR vs 8/26 (30.7%) LRa |
Vargas 2016 | N/A | 14/25 (56%) | N/A | N/A | HPV 83 16,62, 68,81,59,51, 31, 45,6108,34,82, 73,71,67,54,53,52 | 11/14 (78.5%) HR vs 10/14 (71.4%) LRa |
Lopez-Diez 2017 | N/A | 63/125 (50.4%) | N/A | N/A | HPV 16 18, 33,52,51,31,39 45,56,58,59,53,66, 67,68,69,70,73 | N/A |